



## NEWS RELEASE

### **Orion Nutraceuticals Applies for Extension of Management Cease Trade Order**

**Vancouver, British Columbia – November 26, 2019 – Orion Nutraceuticals Inc., (CSE: ORI) (the “Company” or “Orion”)** announces that it has made an application to the British Columbia Securities Commission (“BCSC”) to approve an extension to its existing management cease trade order (“MCTO”) under National Policy 12-203 *Cease Trade Orders for Continuous Disclosure Defaults* (“NP 12-203”), which, if granted, will continue to prohibit trading in securities of the Company by certain insiders of the Company, whether direct or indirect.

The Company was granted an MCTO by the BCSC on October 1, 2019. The Company has previously advised that it expected to be in a position to file the financial statements and accompanying management’s discussion and analysis of the Company for the fiscal year ended May 31, 2019 (the “Annual Filings”) on or before November 29, 2019.

The Company has been informed by its auditor, DMCL LLP, that it would not be in a position to complete the audit by November 29, 2019. The Company has been working diligently with DMCL LLP to ensure that the audit is completed as soon possible. The Company has now applied to extend the MCTO and anticipates being in a position to file the Annual Filings by December 13, 2019.

The existing MCTO presently continues to be in effect.

The Company confirms that it intends to satisfy the provisions of the alternative information guidelines set out in section 4.3 and 4.5 of NP12-203 so long as it remains in default of filing the Annual Filings.

There is no material information concerning the affairs of the Company which has not been generally disclosed.

#### **About Orion Nutraceuticals Inc.**

Orion Nutraceuticals Inc. aims to set a new standard in cannabis life science by producing and developing innovative products with key strategic partners in the industry. In conjunction with its professional sports strategic alliances, the company is poised to advance research and development in the plant science sector, deliver science-based products and services, and market CBD therapies to the mainstream with proprietary brands and products. Orion shares trade in Canada on the CSE under the symbol ORI.

#### **ON BEHALF OF THE BOARD**

“Joel Dumaresq”  
Joel Dumaresq, CEO

Orion Nutraceuticals Inc.  
[www.orionnutra.ca](http://www.orionnutra.ca)

Investor Relations  
[investors@orionnutra.ca](mailto:investors@orionnutra.ca)



Keep up to date with Orion on our social media channels:

Twitter: @orionnutra

Facebook: @orionnutra

Instagram: @orionnutra

LinkedIn: @orionnutra

Cautionary Note Regarding Forward-Looking Statements: Information in this press release that involves Orion's expectations, plans, intentions or strategies regarding the future are forward-looking statements that are not facts and involve a number of risks and uncertainties. Orion generally uses words such as "outlook," "will," "could," "would," "might," "remains," "to be," "plans," "believes," "may," "expects," "intends," "anticipates," "estimate," "future," "plan," "positioned," "potential," "project," "remain," "scheduled," "set to," "subject to," "upcoming," and similar expressions to help identify forward-looking statements. In this press release, forward-looking statements include statements regarding: the timing and completion of necessary accounting and review procedures to complete the Annual Filings and other factors beyond our control. Forward-looking statements reflect the then-current expectations, beliefs, assumptions, estimates and forecasts of Orion's management. The forward-looking statements in this press release are based upon information available to Orion as of the date of this press release. Forward-looking statements believed to be true when made may ultimately prove to be incorrect. These statements are not guarantees of the future performance of Orion and are subject to a number of risks, uncertainties and other factors, some of which are beyond its control and may cause actual results to differ materially from current expectations, including without limitation: failure to negotiate and enter into a definitive agreement with Molecular You; failure to meet regulatory requirements; changes in the market; potential downturns in economic conditions; and other risk factors described in Orion's public filings available on SEDAR at [www.sedar.com](http://www.sedar.com). Accordingly, readers should exercise caution in relying upon forward-looking statements and Orion undertakes no obligation to publicly revise them to reflect subsequent events or circumstances, except as required by applicable law.

***The CSE and Information Service Provider have not reviewed and does not accept responsibility for the accuracy or adequacy of this release.***